NVIDIA Expands Generative AI Drug Discovery Platform BioNeMo with Collaborations from Amgen and Recursion

Leader in Artificial Intelligence ComputingNVIDIA（NVIDIA) Has successively invested in several AI drug development companies in the past year, and its ambitions in the field of drug development are becoming the focus of attention worldwide.

The other day, NVIDIA announced three new initiatives, includingAmgen（Amgen）SubsidiarydeCodeTo embark on new collaborations.NVIDIA stated that DECODE will leverage NVIDIA's supercomputers andBioNeMoGenerative AI Platform Powers Its New Genomics Foundation Model.BioNeMo is a set of programs by NVIDIA aimed at accelerating drug discovery.Introduction: This is an emerging platform that combines many foundational models, allowing users to supplement it with their own data.

Just as programming languages like R and Python are crucial for data science, the packages in BioNeMo aim to play a similar role in drug development. NVIDIA stated that this month, it will be available on the BioNeMo platform.Launched cloud API interface and released the foundational model MolMIM。

Currently, Recursion has joined NVIDIA's generative AI-based drug discovery platform.BioNeMo, becoming the first third-party company on the BioNeMo platform, with its CEOChris Gibson,Recursion is a step ahead in building an internal operating system that converts cell images into recognizable research findings about cell states, allowing versions of the program to be made available to a broader industry. We believe this prospect is as vast and exciting as genomics.

Recursion's efforts have made it a leading company in AI-based drug development.Has a large number of clinical-stage assets in the fields of rare diseases and oncology,Such companies are usually referred to astechbio`, namely, so-called platform companies`, especially referring to companies that develop new drugs using computational biology or AI-prioritized biological methods. Recursion's work has also attracted collaborations with Bayer and Roche.。

On January 10th, at the JP Morgan conference,Recursion and NVIDIA will co-host an invitation-only event, where they will launch and demonstrateRRecursion's Artificial Intelligence Drug Discovery Software——LOWELOWE is a large language model-based（LLM）'s new software, which can perform complex drug discovery tasks and coordinate wet lab and dry lab experiments using a natural language interface, therefore, regardless ofWhether or not they have received formal training in machine learning, they can access the most advanced artificial intelligence algorithms and computing tools,In addition, LOWE also provides extensive data visualization.